Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)-Protocol for a Nested Qualitative Study
ABSTRACT Introduction Bipolar disorder is a recurrent mental health disorder with a prevalence rate of 1.4%. On average, there can be a delay of 9.5 years from the initial presentation of symptoms to a confirmed diagnosis. Individuals living with bipolar disorder have a reduced life expectancy. Ther...
Saved in:
Main Authors: | Isobel Hoppe (Author), Stuart Watson (Author), Caroline Kemp (Author), Fiona Turnbull (Author), Firoza Davies (Author), John Gibson (Author), Lumbini Azim (Author), Lauren Wall (Author), Niraj Ahuja (Author), Sarah Al‐Ashmori (Author), Sally Keys (Author), Thomas Kabir (Author), Carolyn A. Chew‐Graham (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aripiprazole in the acute and maintenance phase of bipolar I disorder
by: Zupancic M, et al.
Published: (2012) -
Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
by: Kirino E
Published: (2014) -
Quetiapine for acute bipolar depression: a systematic review and meta-analysis
by: Suttajit S, et al.
Published: (2014) -
Post‐marketing surveillance of quetiapine fumarate extended‐release tablets in patients with bipolar depression
by: Taro Kishi, et al.
Published: (2024) -
Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
by: Taro Kishi, et al.
Published: (2019)